Literature DB >> 29629902

Humanized mouse model of Rasmussen's encephalitis supports the immune-mediated hypothesis.

Hania Kebir1,2, Lionel Carmant3,4,5, François Fontaine3,4, Kathie Béland3, Ciprian M Bosoi3, Nathalie T Sanon3, Jorge I Alvarez6, Sébastien Desgent3, Camille L Pittet2, David Hébert3, Marie-Josée Langlois3, Rose-Marie Rébillard4, Dang K Nguyen2,5, Cécile Cieuta-Walti7, Gregory L Holmes8, Howard P Goodkin9, John R Mytinger9, Mary B Connolly10, Alexandre Prat2,5, Elie Haddad1,3,4.   

Abstract

Rasmussen's encephalitis (RE) is a chronic inflammatory brain disorder that causes frequent seizures and unilateral hemispheric atrophy with progressive neurological deficits. Hemispherectomy remains the only treatment that leads to seizure freedom for this refractory epileptic syndrome. The absence of an animal model of disease has been a major obstacle hampering the development of effective therapies. Here, we describe an experimental mouse model that shares several clinical and pathological features with the human disease. Immunodeficient mice injected with peripheral blood mononuclear cells from RE patients and monitored by video electroencephalography developed severe seizures of cortical origin and showed intense astrogliosis and accumulation of human IFN-γ- and granzyme B-expressing T lymphocytes in the brain compared with mice injected with immune cells from control subjects. We also provide evidence for the efficacy of α4 integrin blockade, an approved therapy for the treatment of multiple sclerosis and Crohn's disease, in reducing inflammatory markers associated with RE in the CNS. This model holds promise as a valuable tool for understanding the pathology of RE and for developing patient-tailored experimental therapeutics.

Entities:  

Keywords:  Immunology; Immunotherapy; Mouse models; Neurological disorders; Neuroscience

Mesh:

Year:  2018        PMID: 29629902      PMCID: PMC5919802          DOI: 10.1172/JCI97098

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  46 in total

1.  Focal seizures due to chronic localized encephalitis.

Authors:  T RASMUSSEN; J OLSZEWSKI; D LLOYDSMITH
Journal:  Neurology       Date:  1958-06       Impact factor: 9.910

2.  Development of a human adaptive immune system in cord blood cell-transplanted mice.

Authors:  Elisabetta Traggiai; Laurie Chicha; Luca Mazzucchelli; Lucio Bronz; Jean-Claude Piffaretti; Antonio Lanzavecchia; Markus G Manz
Journal:  Science       Date:  2004-04-02       Impact factor: 47.728

Review 3.  Rasmussen's encephalitis.

Authors:  Yvonne Hart
Journal:  Epileptic Disord       Date:  2004-09       Impact factor: 1.819

4.  Local-clonal expansion of infiltrating T lymphocytes in chronic encephalitis of Rasmussen.

Authors:  Y Li; A Uccelli; K D Laxer; M C Jeong; H V Vinters; W W Tourtellotte; S L Hauser; J R Oksenberg
Journal:  J Immunol       Date:  1997-02-01       Impact factor: 5.422

Review 5.  Humanized mice for immune system investigation: progress, promise and challenges.

Authors:  Leonard D Shultz; Michael A Brehm; J Victor Garcia-Martinez; Dale L Greiner
Journal:  Nat Rev Immunol       Date:  2012-10-12       Impact factor: 53.106

6.  GluR3 autoantibodies destroy neural cells in a complement-dependent manner modulated by complement regulatory proteins.

Authors:  K D Whitney; J O McNamara
Journal:  J Neurosci       Date:  2000-10-01       Impact factor: 6.167

7.  Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis.

Authors:  S W Rogers; P I Andrews; L C Gahring; T Whisenand; K Cauley; B Crain; T E Hughes; S F Heinemann; J O McNamara
Journal:  Science       Date:  1994-07-29       Impact factor: 47.728

8.  Medical treatment of Rasmussen's syndrome (chronic encephalitis and epilepsy): effect of high-dose steroids or immunoglobulins in 19 patients.

Authors:  Y M Hart; M Cortez; F Andermann; P Hwang; D R Fish; O Dulac; K Silver; N Fejerman; H Cross; A Sherwin
Journal:  Neurology       Date:  1994-06       Impact factor: 9.910

9.  Rasmussen encephalitis: incidence and course under randomized therapy with tacrolimus or intravenous immunoglobulins.

Authors:  Christian G Bien; Henning Tiemeier; Robert Sassen; Stefan Kuczaty; Horst Urbach; Marec von Lehe; Albert J Becker; Thomas Bast; Peter Herkenrath; Michael Karenfort; Bernd Kruse; Gerhard Kurlemann; Sabine Rona; Susanne Schubert-Bast; Silvia Vieker; Stefan Vlaho; Bernd Wilken; Christian E Elger
Journal:  Epilepsia       Date:  2012-12-06       Impact factor: 5.864

10.  A humanized mouse model of idiopathic nephrotic syndrome suggests a pathogenic role for immature cells.

Authors:  Anne-Laure Sellier-Leclerc; Arnaud Duval; Stéphanie Riveron; Marie-Alice Macher; Georges Deschenes; Chantal Loirat; Marie-Christine Verpont; Michel Peuchmaur; Pierre Ronco; Renato C Monteiro; Elie Haddad
Journal:  J Am Soc Nephrol       Date:  2007-09-12       Impact factor: 10.121

View more
  7 in total

1.  Pro-inflammatory, IL-17 pathways dominate the architecture of the immunome in pediatric refractory epilepsy.

Authors:  Pavanish Kumar; Derrick Chan Wei Shih; Amanda Lim; Bhairav Paleja; Simon Ling; Lai Li Yun; Su Li Poh; Adeline Ngoh; Thaschawee Arkachaisri; Joo Guan Yeo; Salvatore Albani
Journal:  JCI Insight       Date:  2019-03-26

Review 2.  Fundamental mechanistic insights from rare but paradigmatic neuroimmunological diseases.

Authors:  Heinz Wiendl; Catharina C Gross; Jan Bauer; Doron Merkler; Alexandre Prat; Roland Liblau
Journal:  Nat Rev Neurol       Date:  2021-05-28       Impact factor: 42.937

3.  CD8+ T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome.

Authors:  Catharina C Gross; Céline Meyer; Urvashi Bhatia; Lidia Yshii; Ilka Kleffner; Jan Bauer; Anna R Tröscher; Andreas Schulte-Mecklenbeck; Sebastian Herich; Tilman Schneider-Hohendorf; Henrike Plate; Tanja Kuhlmann; Markus Schwaninger; Wolfgang Brück; Marc Pawlitzki; David-Axel Laplaud; Delphine Loussouarn; John Parratt; Michael Barnett; Michael E Buckland; Todd A Hardy; Stephen W Reddel; Marius Ringelstein; Jan Dörr; Brigitte Wildemann; Markus Kraemer; Hans Lassmann; Romana Höftberger; Eduardo Beltrán; Klaus Dornmair; Nicholas Schwab; Luisa Klotz; Sven G Meuth; Guillaume Martin-Blondel; Heinz Wiendl; Roland Liblau
Journal:  Nat Commun       Date:  2019-12-18       Impact factor: 14.919

4.  Targeting Inflammatory Mediators in Epilepsy: A Systematic Review of Its Molecular Basis and Clinical Applications.

Authors:  Giorgio Costagliola; Greta Depietri; Alexandre Michev; Antonella Riva; Thomas Foiadelli; Salvatore Savasta; Alice Bonuccelli; Diego Peroni; Rita Consolini; Gian Luigi Marseglia; Alessandro Orsini; Pasquale Striano
Journal:  Front Neurol       Date:  2022-03-11       Impact factor: 4.003

5.  Editorial: Update on Translational Neuroimmunology - Research of ISNI 2018.

Authors:  Lesley Probert; Francisco J Quintana; Amit Bar-Or
Journal:  Front Immunol       Date:  2020-09-30       Impact factor: 7.561

6.  An immunotherapy effect analysis in Rasmussen encephalitis.

Authors:  Zuzana Liba; Martina Vaskova; Josef Zamecnik; Jana Kayserova; Hana Nohejlova; Matyas Ebel; Jan Sanda; Gonzalo Alonso Ramos-Rivera; Klara Brozova; Petr Liby; Michal Tichy; Pavel Krsek
Journal:  BMC Neurol       Date:  2020-09-24       Impact factor: 2.474

7.  Rasmussen's encephalitis is characterized by relatively lower production of IFN-β and activated cytotoxic T cell upon herpes viruses infection.

Authors:  Yi-Song Wang; Dong Liu; Xin Wang; Qiao-Li Luo; Ling Ding; Dong-Ying Fan; Qi-Liang Cai; Chong-Yang Tang; Wei Yang; Yu-Guang Guan; Tian-Fu Li; Pei-Gang Wang; Guo-Ming Luan; Jing An
Journal:  J Neuroinflammation       Date:  2022-03-26       Impact factor: 8.322

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.